Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Editas Medicine

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Editas Medicine reports positive clinical data and strategic advancements

Editas Medicine's Q4 2022 earnings call highlighted positive clinical data, strong financial positioning, and strategic advancements in genome editing medicines.
While facing challenges in hiring key personnel, regulatory negotiations, and strategic realignment, the company is well-positioned for therapeutic advancements and market growth.
Opportunities lie in replicating clinical success, strategic partnerships, and advancements in pipeline development, supported by strong collaborations and financial prospects.
Overall, Editas Medicine's performance, strengths, challenges, and opportunities reflect a company poised for continued growth and innovation in the genome editing space.

Editas Medicine excels in Q1 with promising trials and regulatory progress

Editas Medicine's Q1 performance was strong, supported by promising clinical trial data and regulatory advancements.
The company's focus on gene editing for hemoglobinopathies and strong IP position are key strengths.
Challenges include differentiation from competitors and legal uncertainties, while opportunities lie in expansion and regulatory progress.
Overall, Editas Medicine is well-positioned for growth in the gene editing market.

Editas Medicine reports positive data, raises funds, and faces challenges

Editas Medicine shows strong performance with positive clinical data and financial raise
Facing challenges in pipeline adjustment and FDA discussions for facility planning
Opportunities lie in expanding trials, partnerships, and enhancing R&D focus

Editas Medicine advances EDIT-301 program, poised for gene therapy leadership

Editas Medicine is making significant progress with EDIT-301, showcasing confidence in their gene editing capabilities and operational readiness.
While facing challenges in safety monitoring and differentiation, the company's strategic hires, strong IP portfolio, and focus on regulatory pathways provide a solid foundation for growth.
With a clear roadmap for clinical data presentation, manufacturing scaling, and regulatory submissions, Editas is well-positioned to capitalize on opportunities in gene editing therapies.

Editas Medicine exceeds enrollment goals and showcases promising clinical data

Editas Medicine's Q4 2023 Earnings Call showcased strong performance in enrollment, clinical data, and financials. The company's strengths lie in its research capabilities, cash position, and progress in key trials. Challenges include addressing analyst queries and optimizing manufacturing processes.

Editas Medicine reports robust Q1 performance and advances in gene editing

Editas Medicine's Q1 2024 performance reflects solid revenue and strong financial reserves, driven by R&D investments in the Renace program.
The company's strengths lie in its financial stability, advancing in vivo capabilities, and fostering strong collaborations for future growth.
Challenges include legal uncertainties, operational optimizations, and strategic complexities in therapeutic development.
Opportunities abound in driving Renace, regulatory progress for Reni-cel, and leveraging innovative in vivo approaches for unique indications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

On Editas' (EDIT) first-quarter earnings call, investor focus will be on the company's progress with its most advanced pipeline candidate, EDIT-101.

Is a Beat in Store for Editas (EDIT) This Earnings Season?

Editas (EDIT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Editas Medicine (EDIT) Expected to Beat Earnings Estimates: Should You Buy?

bluebird bio

Bristol-Myers

Celgene

CRISPR Therapeutics

Guardant Health Inc

Genomic Health

Gilead Sciences

Illumina

Myriad Genetics

Novartis

Invitae

Spark Therapeutics

Pacific Biosciences of California

REGENXBIO

Roche Holding AG

Thermo Fisher Scientific

These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

Top Gene-Sequencing Stocks for 2019

Huami, Tanger, and Editas Medicine have small market caps, but that only leaves them more room for multibagger returns.

3 Top Small-Cap Stocks to Buy in April: Editas Medicine

If CRISPR therapies pan out, the possibilities are vast.

How Editas Medicine Could Make You Better (and Richer)

Cara Therapeutics

Genfit - ADR

They're risky, but these up-and-coming biotechs could be tremendous winners for investors willing to take on those risks.

3 Top Small-Cap Biotech Stocks for Aggressive Investors

The gene-editing specialist continues to move toward commercialization of its primary drug candidate.

Why Editas Medicine Stock Popped 18.5% in March

Editas Medicine signed a collaboration deal with oncology player BlueRock Therapeutics on Wednesday — following in the footsteps of other CRISPR gene-editing companies. Editas stock lifted.

CRISPR Stock Inks Deal To Use Stem Cells In Gene-Editing Medicine

Nektar Therapeutics

Viking Therapeutics

Here's why Wall Street thinks these stocks could generate returns of 100% or more in the next 12 months.

Three Stocks That Could Double Your Money

News for Editas Medicine Stock (EDIT)